NCT06590246View on ClinicalTrials.gov

A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/recurrent Hepatocellular Carcinoma (HCC)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2043

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

Armored and GPC3-targeted autologous CAR T-cell

Armored and GPC3-targeted autologous CAR T-cells, single infusion intravenously.

All Listed Sponsors
lead

Shanghai AbelZeta Ltd.

INDUSTRY

NCT06590246 - A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/recurrent Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter